220 related articles for article (PubMed ID: 24580046)
1. Managing hepatitis B to prevent liver cancer: recent advances.
Strasser SI
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):409-15. PubMed ID: 24580046
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Singal AK; Salameh H; Kuo YF; Fontana RJ
Aliment Pharmacol Ther; 2013 Jul; 38(2):98-106. PubMed ID: 23713520
[TBL] [Abstract][Full Text] [Related]
3. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Triolo M; Della Corte C; Colombo M
Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
5. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
6. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
Abu-Amara M; Feld JJ
Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination.
Kim MN; Han KH; Ahn SH
Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736
[TBL] [Abstract][Full Text] [Related]
8. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
9. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV; Dalekos GN; Yurdaydin C; Buti M; Goulis J; Arends P; Sypsa V; Manolakopoulos S; Mangia G; Gatselis N; Keskın O; Savvidou S; Hansen BE; Papaioannou C; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2015 Feb; 62(2):363-70. PubMed ID: 25195548
[TBL] [Abstract][Full Text] [Related]
11. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy.
Halegoua-De Marzio D; Hann HW
Minerva Gastroenterol Dietol; 2014 Sep; 60(3):191-200. PubMed ID: 25000955
[TBL] [Abstract][Full Text] [Related]
13. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
Kumada T; Toyoda H; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Niinomi T; Yasuda S; Andou Y; Yamamoto K; Tanaka J
J Hepatol; 2013 Mar; 58(3):427-33. PubMed ID: 23123221
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
15. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
16. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Kim BK; Han KH; Ahn SH
Oncology; 2011; 81 Suppl 1():41-9. PubMed ID: 22212935
[TBL] [Abstract][Full Text] [Related]
17. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
19. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
20. [Chronic hepatitis B: current therapy].
Buffet C
Bull Acad Natl Med; 2008 Nov; 192(8):1625-37; discussion 1638-9. PubMed ID: 19445377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]